Navigation Links
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
Date:9/21/2008

eva Pharmaceutical Industries Ltd.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

Isis Forward-Looking Statement

This press release includes forward-looking statements regarding Isis' business, its drug discovery and development pipeline, and the therapeutic potential of ATL/TV1102 for the treatment of multiple sclerosis. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or pro
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.; Antisense Therapeutics Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 Lazarus Effect, a medical device ... to facilitate removal of blood clots, announced the closing ... will support EU commercialization of several approved Lazarus Effect ... ReCover™ and Lazarus Cover™ in the United ... confidence in the value of our novel, platform technology ...
(Date:7/31/2014)... and VIENNA , July 31, ... a press conference in New York ... a vaccine against Parkinson,s disease. PD01A is the first therapy ... enter clinical testing. The Michael J. Fox Foundation ... 1.5 million grant, and presented at the press conference on ...
(Date:7/31/2014)... NORTHBROOK, Ill. , July 31, 2014 /PRNewswire/ ... as the head of corporate and employee communications ... to Jeff Winton , senior vice president, ... be responsible for developing and leading corporate brand ... business goals across North and South ...
Breaking Medicine Technology:Lazarus Effect Closes $5 Million Financing 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2
... ... research and biotechnology companies are testing 97 medicines and vaccines to ... report released today by the Pharmaceutical Research and Manufacturers of America ... - a global awareness campaign that originated at the 1988 World ...
... , XI,AN, China, Nov. ... a leading developer and producer,of plant extracts and pharmaceutical raw ... China, today reported that in its,third quarter, the company realized ... Revenues for the quarter ended Sept. 30, 2009 were $4,465,770, ...
Cached Medicine Technology:New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 4
(Date:7/31/2014)... 2014 The team at Advanced ... NJ, is proud to announce that they are ... PMR proudly offers many services, including Physical Therapy, ... medical supplies. Some of their physical therapy services ... geriatric therapy among a vast list of others. ...
(Date:7/31/2014)... In a front-page story, the Wall ... & Johnson, is withdrawing its laparoscopic power morcellator due ... This important story has also been reported by ... AP (7/30), the Pittsburgh Business Times (7/30) and TIME ... uterine procedures to, “slice up common uterine masses called ...
(Date:7/31/2014)... , Rest assured, there is a happy ending, ... shows that many college students are stressed out and ... there are simple ways for students to relieve stress ... of UC,s Health Promotion and Education Program. The trouble ... a whole array of different stress-management techniques college students ...
(Date:7/31/2014)... The Never Give Up 26 Foundation looks forward to seeing ... Simply bring your ticket and Mention Never Give Up 26 ... and family. , Packy had unique internal drives, ... optimism continues to impact the lives of many. Overcoming ... a happy life was truly a testament to his character. ...
(Date:7/31/2014)... The “Nucleic Acid Isolation and Purification ... bead based), Consumables & Instruments, by Application (Plasmid ... users - Global Forecasts to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... with the estimates and forecasts of the revenue ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs' Approved, Advanced Physical Medicine and Rehabilitation Now Offering Chiropractic & Podiatric Services 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 3Health News:Simple tips to fend off freak-outs 2Health News:Simple tips to fend off freak-outs 3Health News:Don't Forget To Mention Never Give Up 26 Foundation 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 4
... that has been commissioned by the Australian government states that ... cost effective option to control// the growing epidemic of childhood ... found the various programs based in schools were cost-effective, but ... that many ministers for state who are in favour of ...
... Canada can differ according to provinces, says a new study ... ,People on dialysis in Alberta were four times more ... the study conducted over a five-year period found. Saskatchewan, Atlantic ... for kidneys than Ontario. ,"We can say that ...
... The National Institute of Virology in Pune declared Tuesday there ... 250 km from here in south Gujarat.// ,Additional ... samples from Surat city, and not even a single sample ... NIV, have not yet clarified why two persons had died ...
... August 26 issue of "The Lancet" has revealed that ... past decade// in many countries of the world, especially ... University of Auckland, New Zealand, and colleagues repeated the ... between 2002-2003 to assess the global prevalence of asthma, ...
... a Christchurch General Practitioner for allegedly manipulating a sexual ... account, the GP even bought her lingerie and advised ... ,The doctor has been slapped with a charge ... with the woman in question. Allegedly, the former ...
... Board has indicated that the Klein Government is all set ... early stage breast cancer.// The spokeswoman of the board, Lee ... trials in the United Kingdom before advising the $40,000-per-patient drug ... is available to those patients who are in dire need ...
Cached Medicine News:Health News:Health Experts In Australia Toy With The Idea Of Surgery for Controlling Obesity In Teenagers 2Health News:Rise In Childhood Allergies 2
7 mm curved blade. Round handle....
7 mm strong curved blade. Round handle....
3 mm diameter roller blade, 15 mm from angle to tip. Round handle....
No. 4. 0.75 mm wide x 5 mm long, lightly curved tip, offset to the left. Hexagonal handle....
Medicine Products: